Vanguard Group’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-62,418
| Closed | -$1.21M | – | 4353 |
|
|
2024
Q4 | $1.21M | Hold |
62,418
| – | – | ﹤0.01% | 3701 |
|
|
2024
Q3 | $978K | Buy |
62,418
+1
| +0% | +$9 | ﹤0.01% | 3783 |
|
|
2024
Q2 | $527K | Sell |
62,417
-2
| -0% | -$23 | ﹤0.01% | 3987 |
|
|
2024
Q1 | $963K | Hold |
62,419
| – | – | ﹤0.01% | 3831 |
|
|
2023
Q4 | $862K | Sell |
62,419
-651
| -1% | -$7.7K | ﹤0.01% | 3879 |
|
|
2023
Q3 | $721K | Hold |
63,070
| – | – | ﹤0.01% | 3944 |
|
|
2023
Q2 | $1.57M | Sell |
63,070
-7,714
| -11% | -$226K | ﹤0.01% | 3743 |
|
|
2023
Q1 | $2.57M | Buy |
70,784
+333
| +0.5% | +$20.4K | ﹤0.01% | 3586 |
|
|
2022
Q4 | $4.25M | Buy |
70,451
+7,895
| +13% | +$529K | ﹤0.01% | 3385 |
|
|
2022
Q3 | $4.69M | Sell |
62,556
-5,631
| -8% | -$588K | ﹤0.01% | 3365 |
|
|
2022
Q2 | $7.81M | Buy |
68,187
+18,436
| +37% | +$2.16M | ﹤0.01% | 3121 |
|
|
2022
Q1 | $9.42M | Sell |
49,751
-24,548
| -33% | -$5.68M | ﹤0.01% | 3188 |
|
|
2021
Q4 | $25.8M | Buy |
74,299
+43,192
| +139% | +$16.7M | ﹤0.01% | 2704 |
|
|
2021
Q3 | $10.4M | Buy |
31,107
+5,911
| +23% | +$3.03M | ﹤0.01% | 3219 |
|
|
2021
Q2 | $20.8M | Buy |
+25,196
| New | +$19.5M | ﹤0.01% | 2819 |
|
Vanguard Group's OMIC Position: Q1 2025 in Review
Vanguard Group sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q1 2025, closing a stake of 62,418 shares — an estimated $1.21M sold.
Vanguard Group first reported a position in OMIC in Q2 2021 and held it in 15 quarters. The position peaked at $25.8M in Q4 2021. 0 funds tracked by Wall St. Rank hold OMIC as of Q1 2025.
- Vanguard Group reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Vanguard Group sold 62,418 Singular Genomics Systems, Inc. Common Stock shares in Q1 2025, an estimated $1.21M.
- Vanguard Group first reported a position in Singular Genomics Systems, Inc. Common Stock in Q2 2021 and held it in 15 quarters.
- Vanguard Group's Singular Genomics Systems, Inc. Common Stock position peaked at $25.8M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q1 2025.
Based on Vanguard Group's 13F filing for Q1 2025, filed 9 May 2025.